Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Link opens in a new tab
Search content at UTMB Health Research Expert Profiles
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Preclinical Evaluation of a Live Attenuated Chikungunya Vaccine
Jill A. Livengood
, Charalambos D. Partidos
,
Kenneth Plante
, Rob Seymour
, Rodion Gorchakov
, Laszlo Varga
, Joanna Paykel
, James Weger
, Aurelia Haller
, Dan T. Stinchcomb
, Jorge Osorio
,
Scott Weaver
Microbiology And Immunology
Research output
:
Contribution to journal
›
Article
›
peer-review
1
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Preclinical Evaluation of a Live Attenuated Chikungunya Vaccine'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Live Attenuated
100%
Preclinical Evaluation
100%
Chikungunya Virus (CHIKV)
100%
Chikungunya Vaccine
100%
Virus Vaccine
40%
Public Health
20%
Complementary DNA (cDNA)
20%
Vaccine Strain
20%
Fever
20%
Preclinical Development
20%
Immunogenic
20%
Internal Ribosome Entry Site
20%
Structural Protein Genes
20%
Encephalomyocarditis Virus
20%
Mosquito Vectors
20%
Clinical Testing
20%
Human Trials
20%
Nonhuman Primate
20%
Arthritis
20%
Mandatory Vaccines
20%
Africa
20%
Subgenomic Promoter
20%
Travellers
20%
Italy
20%
Development Effort
20%
South-East Asia
20%
Indian Subcontinent
20%
Highly Stable
20%
Synonymous mutation
20%
Investigational New Drug
20%
Attenuation Mechanism
20%
Medicine and Dentistry
Chikungunya
100%
Chikungunya Virus
100%
Virus Vaccine
40%
Public Health
20%
Infection
20%
Promoter Region
20%
Complementary DNA
20%
Mosquito Vector
20%
Structural Protein
20%
Internal Ribosome Entry Site
20%
Vaccine Strain
20%
Arthritis
20%
Encephalomyocarditis Virus
20%
Attenuation Mechanisms
20%
Pre-Clinical Development
20%
Pharmacology, Toxicology and Pharmaceutical Science
Chikungunya
100%
Chikungunya Virus
100%
Virus Vaccine
40%
Infection
20%
Vaccine Strain
20%
Structural Protein
20%
Complementary DNA
20%
Mosquito Vector
20%
Arthritis
20%
Encephalomyocarditis Virus
20%
Immunology and Microbiology
Chikungunya Virus
100%
Virus Vaccine
40%
Promoter Region
20%
Preclinical Study
20%
Encephalomyocarditis Virus
20%
Internal Ribosome Entry Site
20%
Arthritis
20%
Structural Protein
20%
Infection
20%
Attenuation Mechanisms
20%
Biochemistry, Genetics and Molecular Biology
Chikungunya Virus
100%
Promoter Region
20%
Structural Protein
20%
Internal Ribosome Entry Site
20%
Encephalomyocarditis Virus
20%
Preclinical Study
20%
Attenuation Mechanisms
20%